| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 170.771 | 95.433 | 108.751 | 204.748 | 234.255 | 315.016 | 250.374 | 303.856 | 220.449 | 339.099 |
| Total Income - EUR | 211.945 | 114.123 | 129.050 | 257.110 | 259.872 | 342.203 | 296.539 | 396.514 | 343.928 | 364.756 |
| Total Expenses - EUR | 210.151 | 122.783 | 133.582 | 258.536 | 246.744 | 273.109 | 259.957 | 389.876 | 334.776 | 354.797 |
| Gross Profit/Loss - EUR | 1.794 | -8.660 | -4.531 | -1.426 | 13.128 | 69.094 | 36.582 | 6.637 | 9.152 | 9.959 |
| Net Profit/Loss - EUR | 1.224 | -8.660 | -6.468 | -3.470 | 10.782 | 66.267 | 34.357 | 3.274 | 5.899 | 764 |
| Employees | 5 | 4 | 5 | 7 | 8 | 6 | 7 | 8 | 7 | 6 |
Check the financial reports for the company - Top-Ovirox Comexim Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 27.323 | 10.978 | 6.423 | 3.924 | 5.596 | 8.144 | 45.596 | 38.588 | 29.314 | 48.628 |
| Current Assets | 40.918 | 44.358 | 74.173 | 110.326 | 95.678 | 114.319 | 106.716 | 116.977 | 181.490 | 115.960 |
| Inventories | 35.811 | 37.969 | 32.813 | 64.137 | 54.206 | 62.381 | 80.116 | 106.831 | 168.472 | 100.348 |
| Receivables | 3.321 | 5.451 | 30.861 | 37.968 | 36.549 | 27.728 | 22.833 | 5.509 | 9.553 | 8.655 |
| Cash | 1.785 | 937 | 10.498 | 8.222 | 4.923 | 24.211 | 3.766 | 4.636 | 3.465 | 6.956 |
| Shareholders Funds | 28.931 | 19.802 | 12.686 | 8.939 | 19.529 | 52.697 | 89.112 | 92.577 | 98.194 | 98.121 |
| Social Capital | 5.737 | 5.678 | 5.582 | 5.480 | 5.374 | 5.272 | 5.155 | 5.171 | 5.155 | 5.126 |
| Debts | 39.310 | 35.534 | 67.909 | 105.311 | 81.746 | 69.766 | 63.200 | 62.988 | 112.610 | 66.467 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "1610 - 1610" | |||||||||
| CAEN Financial Year |
1610
|
|||||||||
Comments - Top-Ovirox Comexim Srl